Hepatic resection is superior to transarterial chemoembolization for treating intermediate-stage hepatocellular carcinoma

Jian-Hong Zhong^{1

2}, Ning-Fu Peng^{1

2}, Xue-Mei You^{1

2}, Liang Ma^{1

2}, Le-Qun Li^{1

2}

Affiliations

¹ Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
² Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, China.

Comment

Jian-Hong Zhong et al. Liver Int. 2017 Jul.

. 2017 Jul;37(7):1083-1084.

doi: 10.1111/liv.13290. Epub 2016 Nov 19.

Jian-Hong Zhong^{1

2}, Ning-Fu Peng^{1

2}, Xue-Mei You^{1

2}, Liang Ma^{1

2}, Le-Qun Li^{1

2}

¹ Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
² Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, China.

No abstract available

Comment on

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group. Pecorelli A, et al. Liver Int. 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2. Liver Int. 2017. PMID: 27566596